Mode
Text Size
Log in / Sign up
N/A N=3,587 Randomized Health Services Research

Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation

Substance-related Disorders

Enrolled (actual)
3,587
Serious AEs
Results posted
May 2023
Primary outcome: Primary: Change in Provision of Addiction Treatments — 66; 20; 268; 33 Participants — p=0.55

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Implementation Facilitation (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Yale University
Primary completion
Sep 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Provision of Addiction Treatments
66; 20; 268; 38; 15; 190 0.59
PRIMARY
Change in Provision of Addiction Treatments
66; 20; 268; 38; 15; 190 0.59
SECONDARY
Antiretroviral Therapy (ART) Receipt
4106; 3508
SECONDARY
Antiretroviral Therapy (ART) Receipt
4106; 3508
SECONDARY
Viral Suppression
3849; 2830
SECONDARY
Viral Suppression
3849; 2830
SECONDARY
VACS Index
23.53; 25.12
SECONDARY
VACS Index
23.53; 25.12
SECONDARY
Retention in HIV Care
3450
SECONDARY
Retention in HIV Care
3450
SECONDARY
Organizational Readiness
4.37; 4.05; 4.13
SECONDARY
Organizational Readiness
4.37; 4.05; 4.13
SECONDARY
Provider Readiness
6.75; 6.22; 7.24
SECONDARY
Provider Readiness:
7.28; 7.16; 7.50

Summary

Tobacco, alcohol and opioid use disorders threaten the health of HIV-infected patients. What if evidence-based counseling and medication treatments for tobacco, alcohol and opioid use disorders (herein refered to as addiction treatments) were routinely provided in HIV clinics? Implementation Facilitation is an established strategy to increase the uptake of evidence-based treatments. Our goal is to evaluate the impact of Implementation Facilitation on the use of addiction treatments in four large HIV clinics. The purpose of the WHAT-IF study is: Aim 1. Among key stakeholders, to use quantitative and qualitative (mixed) methods to identify the site-specific evidence, context and facilitation-related barriers and facilitators to the integration of addiction treatments to help tailor an Implementation Facilitation for each clinic. Aim 2. To evaluate the impact of Implementation Facilitation on: 2a: Organizational readiness to deliver addiction treatments 2b: Provider readiness to deliver addiction treatments 2c: Provision of addiction treatments 2d: Changes in organizational models of care used to deliver addiction treatments Aim 3. To evaluate the impact of Implementation Facilitation on antiretroviral therapy receipt, HIV viral suppression, VACS Index, and retention in HIV care among patients eligible for addiction treatment.

Eligibility Criteria

Inclusion Criteria

Patient inclusion criteria:

  • HIV-infected
  • Receiving HIV care in the index clinic
  • Age >18 years old
  • Meets criteria for lifetime or current tobacco, alcohol and/or opioid use disorder regardless of addiction treatment status
  • Able to provide verbal informed consent

Staff inclusion criteria:

  • Employed at participating HIV clinic for at least 6 months
  • Able to provide verbal informed consent.

Payer/health insurance provider inclusion criteria:

  • Employed at an organization or agency that provides funding for medical services for HIV-infected individuals for at least 6 months.
  • Able to provide verbal informed consent.

Exclusion Criteria

  • Unable to provide verbal informed consent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02907944). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search